Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2020

13.03.2020 | short review

Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer

Which way to go?

verfasst von: Fabian Lunger, MD, PhD, Georgios Peros, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary

In locally advanced rectal cancer, neoadjuvant chemoradiotherapy provides a significant benefit to local cancer control in addition to total mesorectal excision. However, in 10–40% of all patients, a complete clinical remission can be detected after completion of chemoradiotherapy. Recent studies have shown that those patients omitting radical surgery after successful neoadjuvant pretreatment can be safely managed within a close follow-up network without compromising short-term overall and disease-free survival. However, available data suggest that 20–30% of all patients assigned to a watch and wait regimen will eventually have to be transferred to surgical management due to local recurrence. Careful patient selection is key for a successful watch and wait approach and the choice of non-operative management should not be made after completion of staging but rather after neoadjuvant chemoradiotherapy. Selected patients need to be thoroughly informed that there is still no standardized follow-up protocol and no predefined follow-up period.
Literatur
5.
Zurück zum Zitat Siddiqui MRS, Simillis C, Bhoday J, Battersby NJ, Mok J, Rasheed S, et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer. 2018;104:47–61. https://​doi.​org/​10.​1016/​j.​ejca .2018.07.131. CrossRef Siddiqui MRS, Simillis C, Bhoday J, Battersby NJ, Mok J, Rasheed S, et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer. 2018;104:47–61. https://​doi.​org/​10.​1016/​j.​ejca .2018.07.131. CrossRef
21.
Zurück zum Zitat van der Valk M, Hilling D, Bastiaannet E, Al E. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45. CrossRef van der Valk M, Hilling D, Bastiaannet E, Al E. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45. CrossRef
23.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://​doi.​org/​10.​1016/​j.​ejca .2008.10.026. CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://​doi.​org/​10.​1016/​j.​ejca .2008.10.026. CrossRef
Metadaten
Titel
Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer
Which way to go?
verfasst von
Fabian Lunger, MD, PhD
Georgios Peros, MD
Publikationsdatum
13.03.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00586-0

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe